Clinical Trials

Phase NA Not yet recruiting

Uterine Cervical Neoplasms

NCT07466901 2026-03-12

A Single-arm, Multicenter, Phase II Clinical Study of Camrelizumab Combined With Famitinib in Adjuvant Therapy After Radical Resection of Cervical Cancer

30 enrolled

Uterine Cervical Neoplasms

NCT05139095 2026-02-05

Camrelizumab Plus Apatinib in Patients With High-risk Gestational Trophoblastic Neoplasia

70 enrolled

Gestational Trophoblastic Disease

NCT06561308 2025-12-01

Clinical Efficacy Study of PD-1 Inhibitor Combined With Neoadjuvant Chemotherapy in Advanced Endometrial Cancer

39 enrolled

Phase 2 Not yet recruiting

Endometrioid Endometrial Cancer

NCT07143292 2025-11-18

A Prospective, Randomized, Parallel Trial of Famitinib Malate at Different Doses Combined With Camrelizumab for the Treatment of Recurrent and Metastatic Cervical Cancer

120 enrolled

Cervical Cancer Metastatic

NCT04680988 2025-08-05

A Study of SHR-1210± SHR-1020 Versus Chemotherapy in Patients With Recurrent or Metastatic Cervical Cancer

Phase 2 Completed

194 enrolled

Uterine Cervical Neoplasms, Recurrence

NCT06288360 2025-03-20

Neoadjuvant Immunochemotherapy in PD-L1-negative LACC

40 enrolled

Uterine Cervical Neoplasms

NCT06289062 2024-11-05

Neoadjuvant Chemotherapy Plus Camrelizumab for FIGO Stage IB1 Cervical Cancer

40 enrolled

Uterine Cervical Neoplasms

NCT06288373 2024-10-30

Neoadjuvant Chemoimmunotherapy Versus Concurrent Chemoradiotherapy for LACC

Phase 2/3 Recruiting

440 enrolled

Uterine Cervical Neoplasms

NCT06413992 2024-05-14

Camrelizumab Plus Fluzoparib for TP-53 Mutated Endometrial Cancer

117 enrolled

Neoplasm Metastasis, Recurrence, Endometrial Neoplasms

NCT03816553 2023-04-11

SHR-1210 in Combination With Apatinib in Patients With Metastatic, Persistent, or Recurrent Cervical Cancer

Phase 2 Completed

45 enrolled

Phase 2 Not yet recruiting

Uterine Cervical Neoplasms

NCT05550558 2022-09-28

CAN-RESPOND

43 enrolled

Endometrial Neoplasms

NCT03827837 2022-07-01

Famitinib Plus Anti-PD1 Therapy for Advanced Urinary System Tumor, Advanced Gynecological Tumors

265 enrolled

GenitourinaryGynecologic

Carcinoma, Renal Cell, Carcinoma, Transitional Cell, Uterine Cervical Neoplasms, Endometrial Neoplasms

NCT04812002 2022-06-03

Study of PD-1 Antibody and Bevacizumab in the Treatment of High-risk GTN After Combined Chemotherapy

20 enrolled

Parkinson Disease 4, Autosomal Dominant Lewy Body, Gestational Trophoblastic Disease

NCT05311566 2022-04-13

PD-1 Antibody Plus Chemoradiotherapy for IB2-IIIB Cervical Cancer

92 enrolled

Uterine Cervical Neoplasms

NCT05151549 2021-12-09

A Study of Carilizumab Combined With Concurrent Chemoradiotherapy

46 enrolled

Uterine Cervical Neoplasms

NCT04974944 2021-10-01

First-line Treatment With Camrelizumab + Apatinib Versus Chemotherapy + Bevacizumab in Advanced Cervical Cancer

172 enrolled

Uterine Cervical Neoplasms

NCT04974827 2021-08-10

A Study of Camrelizumab Combined With Concurrent Chemoradiation in Patients With Cervical Cancer

46 enrolled

Uterine Cervical Neoplasms

NCT04047017 2021-07-30

GTN

Phase 2 Completed

20 enrolled

Recurrence, Gestational Trophoblastic Disease

NCT04884906 2021-05-13

Camrelizumab Combined With Radiotherapy and Chemotherapy for the Treatment of Recurrent or Metastatic Cervical Cancer

40 enrolled

Locally Advanced Cervical Cancer

NCT04068974 2021-03-16

Camrelizumab /Apatinib for Recurrent Platinum-resistant Ovarian Cancer

28 enrolled

Ovarian Neoplasms

NCT04508686 2021-01-29

Combination of Metronomic Capecitabine With Camrelizumab for Treatment of Refractory Solid Tumor Trial (Cohort 1)

Phase 1 Unknown

20 enrolled

Advanced Cervical Cancer

NCT04239443 2020-01-27

Clinical Study of PD-1 Monoclonal Antibody SHR-1210 and Apatinib in Advanced NSCLC, Soft Tissue Sarcoma, and Uterine Cancer